Harvard Bioscience Inc. (NASDAQ:HBIO) shares were down 1.1% during trading on Monday . The company traded as low as $2.76 and last traded at $2.77, with a volume of 86,035 shares trading hands. The stock had previously closed at $2.80.

Separately, Zacks Investment Research upgraded shares of Harvard Bioscience from a “sell” rating to a “hold” rating in a research report on Monday, March 28th.

The company’s 50-day moving average price is $3.31 and its 200 day moving average price is $3.02. The firm’s market cap is $94.03 million.

Harvard Bioscience (NASDAQ:HBIO) last posted its quarterly earnings results on Thursday, May 12th. The company reported $0.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.03. The firm had revenue of $27 million for the quarter, compared to the consensus estimate of $26 million. On average, equities analysts predict that Harvard Bioscience Inc. will post $0.18 EPS for the current fiscal year.

A hedge fund recently raised its stake in Harvard Bioscience stock. Glacier Peak Capital LLC increased its position in shares of Harvard Bioscience Inc. (NASDAQ:HBIO) by 6.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 452,258 shares of the company’s stock after buying an additional 27,514 shares during the period. Harvard Bioscience accounts for about 1.0% of Glacier Peak Capital LLC’s holdings, making the stock its 27th largest position. Glacier Peak Capital LLC owned 1.33% of Harvard Bioscience worth $1,569,000 at the end of the most recent reporting period.

Harvard Bioscience, Inc is a developer, manufacturer and marketer of a range of specialized products, apparatus and scientific instruments. The Company’s products are used to advance life science research at pharmaceutical and biotechnology companies, universities and government laboratories across the world.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.